Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
Michel Seymour(University of Leeds), Philip Quirke(University of Leeds), Jonathan Wadsley(Weston Park Cancer Centre), Alfred Oliver(World Cancer Research Fund International), Kim Benstead(Cheltenham General Hospital), Philip Chambers(University of Leeds), Susan D. Richman(University of Leeds), Ian Chau(Royal Marsden NHS Foundation Trust), Ann O’Callaghan(Portsmouth Hospitals NHS Trust), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Catherine Lowe(University of Hertfordshire), Vicky Napp(University of Leeds), Sarah Brown(University of Leeds), Mark Hill(Maidstone Hospital), Tim Maughan(University of Liverpool), Jennifer Seligmann(University of Leeds), Nick Maisey(National Health Service), Stephen J. Gwyther(East Surrey Hospital), Helen Marshall(University of Leeds), L. Dawson(Edinburgh Cancer Research), Stephen Falk(At Bristol)
Cited by 392
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k